Typical timeline
12–36 months
Among the longest timelines in this database — in-country clinical and testing requirements for higher-risk devices are the main driver.
China
NMPA Registration
China's medical device registration system, among the most demanding globally for higher-risk devices.
Overview
What NMPA is and why it matters
China's National Medical Products Administration (NMPA) regulates devices under a three-class risk system. Class II and III devices generally require type testing at NMPA-accredited laboratories and, in most cases, clinical evaluation or trials conducted within China — a requirement that sets NMPA apart from reliance-based regulators and typically extends timelines well beyond other major markets.
Requirements
What you'll need
The documentation and evidence a complete submission is normally built from.
- Device classification (Class I–III)
- Local agent / legal representative in China
- Type testing at NMPA-accredited laboratories
- Clinical evaluation or in-country clinical trial for most Class II/III devices
- Registration certificate renewal every 5 years
Planning ranges
Typical timeline and estimated cost
Ranges illustrate general market patterns for this pathway — they are not a quote for a specific product.
Estimated cost
$30k–$300k
In-country clinical trials, where required, are the largest cost driver by a wide margin.
Timelines and costs above are typical ranges illustrating general market patterns, not a quote or regulatory conclusion for your specific product. Actual figures depend on device classification, target country, and applicant readiness — professional review is required before relying on this for a business decision.
Where this applies
Applicable countries
Jurisdictions that recognise this certification. Scope and conditions still vary by product classification.
China
Related
Regulatory Pathways
FAQ
Frequently asked questions
Can I use my CE or FDA clinical data in China?
Sometimes, under narrowing exemption criteria — but most Class II/III devices still require some form of China-specific clinical evaluation or trial; this should be confirmed for your specific device with a China-qualified regulatory professional.
Reviewed packages
Buy a defined outcome
Pay for a market-access outcome — not a feature tour
Market Entry Sprint from $2,500 · Strategy Session $500 · Pathway Brief $1,800. Professional review required before business use. No patient data on public forms.
Reviewed launch planning
Need a NMPA pathway brief?
NMPA pathway briefs start at $1,800. Or book a $2,500 Market Entry Sprint that includes regulatory pathway outline, evidence flags, and a review call.
Professional review is required before business use.